Raphael Pharmaceutical (RAPH) Profit After Tax (2020 - 2024)

Raphael Pharmaceutical has disclosed Profit After Tax across 5 years of filings, most recently posting -$395000.0 for Q4 2024.

• Profit After Tax for Q4 2024 came in at -$395000.0, down 423.77% year-over-year; the trailing twelve-month figure through Dec 2024 was -$1.5 million (down 18.3% YoY), and the FY2025 annual result was -$1.3 million, up 15.8% from the prior year.
• Profit After Tax came in at -$395000.0 for Q4 2024 at Raphael Pharmaceutical, down from -$326000.0 in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $122000.0 in Q4 2023 to a low of -$1.4 million in Q3 2022.
• The 5-year median for Profit After Tax is -$391000.0 (2021), against an average of -$458833.3.
• Across the five-year window, Profit After Tax soared 111.06% in 2023 and plunged 423.77% in 2024, its largest moves.
• Raphael Pharmaceutical's Profit After Tax stood at -$230000.0 in 2020, then slumped by 146.52% to -$567000.0 in 2021, then sank by 94.53% to -$1.1 million in 2022, then jumped by 111.06% to $122000.0 in 2023, then slumped by 423.77% to -$395000.0 in 2024.
• The last three Profit After Tax figures came in at -$395000.0 (Q4 2024), -$326000.0 (Q3 2024), and -$248000.0 (Q2 2024), per Business Quant data.